|
AU3445100A
(en)
|
2000-03-24 |
2001-10-08 |
Pharmagene Lab Ltd |
Use of prostanoid ep4 receptor antagonists for the treatment of headache and assays for such antagonists
|
|
HN2001000224A
(es)
|
2000-10-19 |
2002-06-13 |
Pfizer |
Compuestos de imidazol condensado con arilo o heteroarilo como agentes anti - inflamatorios y analgesicos.
|
|
GB0031302D0
(en)
|
2000-12-21 |
2001-01-31 |
Glaxo Group Ltd |
Napthalene derivatives
|
|
GB0031295D0
(en)
|
2000-12-21 |
2001-01-31 |
Glaxo Group Ltd |
Naphthalene derivatives
|
|
GB0103269D0
(en)
|
2001-02-09 |
2001-03-28 |
Glaxo Group Ltd |
Napthalene derivatives
|
|
WO2003086390A1
(en)
|
2002-04-12 |
2003-10-23 |
Pfizer Japan Inc. |
Imidazole compounds as anti-inflammatory and analgesic agents
|
|
WO2003087061A1
(en)
|
2002-04-12 |
2003-10-23 |
Pfizer Japan Inc. |
Pyrazole compounds as anti-inflammatory and analgesic agents
|
|
JP2006506327A
(ja)
|
2002-05-23 |
2006-02-23 |
セラテクノロジーズ インコーポレイティド |
プロスタグランジンｅ２の受容体サブタイプｅｐ４のアンタゴニスト・ポリペプチド
|
|
ES2308139T3
(es)
|
2003-01-29 |
2008-12-01 |
Asterand Uk Limited |
Antagonista de receptos ep4.
|
|
CA2536887C
(en)
*
|
2003-08-26 |
2012-03-06 |
Teijin Pharma Limited |
Pyrrolopyrimidinone derivatives
|
|
CN1867551B
(zh)
|
2003-09-03 |
2013-09-11 |
拉夸里亚创药株式会社 |
作为前列腺素e2拮抗剂的苯基或吡啶基酰胺化合物
|
|
GB0324269D0
(en)
|
2003-10-16 |
2003-11-19 |
Pharmagene Lab Ltd |
EP4 receptor antagonists
|
|
AP2006003769A0
(en)
|
2004-05-04 |
2006-10-31 |
Pfizer |
Ortho substituted aryl or heteroaryl amide compounds
|
|
CN1950333A
(zh)
|
2004-05-04 |
2007-04-18 |
辉瑞大药厂 |
取代的甲基芳基或杂芳基酰胺化合物
|
|
HN2005000795A
(es)
|
2004-10-15 |
2010-08-19 |
Aventis Pharma Inc |
Pirimidinas como antagonistas del receptor de prostaglandina d2
|
|
US8013159B2
(en)
|
2005-05-19 |
2011-09-06 |
Merck Canada Inc. |
Quinoline derivatives as EP4 antagonists
|
|
WO2006128129A2
(en)
|
2005-05-26 |
2006-11-30 |
Synta Pharmaceuticals Corp. |
Method for treating cancer
|
|
EP2013169B1
(en)
|
2006-04-24 |
2012-08-22 |
Merck Canada Inc. |
Indole amide derivatives as ep4 receptor antagonists
|
|
EP2035376B1
(en)
|
2006-06-12 |
2014-08-27 |
Merck Canada Inc. |
Indoline amide derivatives as ep4 receptor ligands
|
|
WO2008008059A1
(en)
|
2006-07-12 |
2008-01-17 |
Locus Pharmaceuticals, Inc. |
Anti-cancer agents ans uses thereof
|
|
BRPI0714409A2
(pt)
|
2006-07-14 |
2013-03-12 |
Novartis Ag |
derivados de pirimidina como inibidores de alk-5
|
|
EP2054401B1
(en)
|
2006-08-11 |
2013-05-01 |
Merck Canada Inc. |
Thiophenecarboxamide derivatives as ep4 receptor ligands
|
|
WO2008039882A1
(en)
|
2006-09-30 |
2008-04-03 |
Sanofi-Aventis U.S. Llc |
A combination of niacin and a prostaglandin d2 receptor antagonist
|
|
JP5301469B2
(ja)
|
2007-02-26 |
2013-09-25 |
メルク カナダ インコーポレイテッド |
Ｅｐ４受容体アンタゴニストとしてのインドール及びインドリンシクロプロピルアミド誘導体
|
|
JPWO2008123207A1
(ja)
|
2007-03-26 |
2010-07-15 |
アステラス製薬株式会社 |
オルニチン誘導体
|
|
US8003661B2
(en)
|
2007-03-26 |
2011-08-23 |
Merck Canada Inc. |
Naphthalene and quinoline sulfonylurea derivatives as EP4 receptor antagonists
|
|
EP2014657A1
(de)
|
2007-06-21 |
2009-01-14 |
Bayer Schering Pharma Aktiengesellschaft |
Diaminopyrimidine als Modulatoren des EP2-Rezeptors
|
|
JP5408434B2
(ja)
|
2007-07-03 |
2014-02-05 |
アステラス製薬株式会社 |
アミド化合物
|
|
EP2565191B1
(en)
|
2008-05-14 |
2014-10-08 |
Astellas Pharma Inc. |
4-(Indol-7-ylcarbonylaminomethyl)cyclohexanecarboxylic acid derivatives as EP4 receptor antagonists useful for the treatment of chronic renal failure or diabetic nephropathy
|
|
WO2010019796A1
(en)
|
2008-08-14 |
2010-02-18 |
Chemietek, Llc |
Heterocyclic amide derivatives as ep4 receptor antagonists
|
|
CN102164942B
(zh)
|
2008-09-19 |
2017-02-15 |
生物科技研究有限公司 |
三萜系化合物及其使用的方法
|
|
CA2737618A1
(en)
|
2008-09-25 |
2010-04-01 |
Merck Frosst Canada Ltd. |
Beta-carboline sulphonylurea derivatives as ep4 receptor antagonists
|
|
US8927547B2
(en)
|
2010-05-21 |
2015-01-06 |
Noviga Research Ab |
Pyrimidine derivatives
|
|
CA2806121C
(en)
|
2010-09-21 |
2018-10-09 |
Eisai R&D Management Co., Ltd. |
Pharmaceutical composition
|
|
JP5273689B2
(ja)
|
2010-09-29 |
2013-08-28 |
株式会社エヌビィー健康研究所 |
ヒトプロスタグランジンｅ２受容体ｅｐ４に対する抗体
|
|
WO2012076063A1
(en)
|
2010-12-10 |
2012-06-14 |
Rottapharm S.P.A. |
Pyridine amide derivatives as ep4 receptor antagonists
|
|
WO2012103071A2
(en)
|
2011-01-25 |
2012-08-02 |
Eisai R&D Management Co., Ltd. |
Compounds and compositions
|
|
DK2688883T3
(en)
*
|
2011-03-24 |
2016-09-05 |
Noviga Res Ab |
pyrimidine
|
|
EP2729445B1
(en)
|
2011-07-04 |
2015-10-21 |
Rottapharm Biotech S.r.l. |
Cyclic amine derivatives as ep4 receptor antagonists
|
|
EP2554662A1
(en)
|
2011-08-05 |
2013-02-06 |
M Maria Pia Cosma |
Methods of treatment of retinal degeneration diseases
|
|
US20150004175A1
(en)
|
2011-12-13 |
2015-01-01 |
Yale University |
Compositions and Methods for Reducing CTL Exhaustion
|
|
JP6378171B2
(ja)
|
2012-04-24 |
2018-08-22 |
バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ |
Ｄｎａ−ｐｋ阻害剤
|
|
AR091429A1
(es)
|
2012-06-29 |
2015-02-04 |
Lilly Co Eli |
Compuestos de fenoxietil piperidina
|
|
TWI572597B
(zh)
|
2012-06-29 |
2017-03-01 |
美國禮來大藥廠 |
二甲基－苯甲酸化合物
|
|
UA115576C2
(uk)
|
2012-12-06 |
2017-11-27 |
Байєр Фарма Акцієнгезелльшафт |
Похідні бензимідазолу як антагоністи ер4
|
|
EP2765128A1
(en)
|
2013-02-07 |
2014-08-13 |
Almirall, S.A. |
Substituted benzamides with activity towards EP4 receptors
|
|
TW201443004A
(zh)
|
2013-02-15 |
2014-11-16 |
Lilly Co Eli |
苯氧基乙氧基化合物
|
|
TWI636046B
(zh)
|
2013-05-17 |
2018-09-21 |
美國禮來大藥廠 |
苯氧基乙基二氫－１ｈ－異喹啉化合物
|
|
HRP20180703T1
(hr)
|
2013-06-12 |
2018-06-15 |
Kaken Pharmaceutical Co., Ltd. |
Derivat 4-alkinil imidazola i lijek koji kao aktivni sastojak sadrži isti
|
|
JP6417419B2
(ja)
|
2013-09-04 |
2018-11-07 |
ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ |
免疫調節剤として有用な化合物
|
|
HRP20181052T1
(hr)
|
2013-09-06 |
2018-09-07 |
Aurigene Discovery Technologies Limited |
Derivati 1,2,4-oksadiazola kao imunomodulatori
|
|
WO2015044900A1
(en)
|
2013-09-27 |
2015-04-02 |
Aurigene Discovery Technologies Limited |
Therapeutic immunomodulating compounds
|
|
PT3057959T
(pt)
|
2013-10-17 |
2018-06-04 |
Vertex Pharma |
Inibidores de adn-pk
|
|
ME02896B
(me)
|
2013-12-17 |
2018-04-20 |
Lilly Co Eli |
Fenoksietilni derivati prstenastog amina i njihova aktivnost kao modulatora receptora ep4
|
|
CN105793236B
(zh)
|
2013-12-17 |
2017-10-10 |
伊莱利利公司 |
二甲基苯甲酸化合物
|
|
TW201607943A
(zh)
|
2013-12-19 |
2016-03-01 |
拜耳製藥公司 |
作為ｅｐ４配體之新穎苯并咪唑衍生物
|
|
TW201623277A
(zh)
|
2014-03-26 |
2016-07-01 |
安斯泰來製藥股份有限公司 |
醯胺化合物
|
|
KR102535283B1
(ko)
|
2014-05-23 |
2023-05-22 |
에자이 알앤드디 매니지먼트 가부시키가이샤 |
암의 치료를 위한 조합 요법
|
|
WO2016021742A1
(en)
|
2014-08-07 |
2016-02-11 |
Takeda Pharmaceutical Company Limited |
Heterocyclic compounds as ep4 receptor antagonists
|
|
WO2016054807A1
(en)
|
2014-10-10 |
2016-04-14 |
Merck Sharp & Dohme Corp. |
TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF
|
|
NZ733575A
(en)
|
2015-01-09 |
2022-10-28 |
Ono Pharmaceutical Co |
Tricyclic spiro compound
|
|
EP3325490B1
(en)
|
2015-07-23 |
2019-12-18 |
Takeda Pharmaceutical Company Limited |
1-substituted 1,2,3,4-tetrahydro-1,7-naphthyridin-8-amine derivatives and their use as ep4 receptor antagonists
|
|
BR112018007664B1
(pt)
|
2015-10-16 |
2023-12-19 |
Eisai R&D Management Co., Ltd |
Compostos antagonistas de ep4, composição compreendendo o composto e uso dos mesmos para tratar câncer
|